慢性阻塞性肺疾病2017版GOLD分类对患者死亡率的预测:一项队列研究
该研究纳入丹麦全国COPD门诊患者33765例(全因死亡主队列,2008年1月1日至2013年11月30日),其中22621例有呼吸特异性死亡数据(亚队列,2008年1月1日至2011年12月31日)。按2007、2011、2017版GOLD分类分组,计算全因和呼吸死亡调整HR并比较预测能力。GOLD 2017的3年全因死亡率从A组10.0%升至D组36.9%,但B组(23.8%)高于C组(17.4%);以A组为参照,全因死亡调整HR:B组2.05(95%CI 1.87-2.26)、C组1.47(1.31-1.65)、D组3.01(2.75-3.30)。全因死亡AUC:GOLD 2007 0.61(0.60-0.61)、2011 0.61(0.60-0.62)、2017 0.63(0.53-0.73);呼吸死亡AUC:2007 0.64(0.62-0.65)、2011 0.63(0.62-0.64)、2017 0.65(0.53-0.78)。仅用ABCD分组时2017版预测并不优于旧版,但细分16个亚组(1A至4D)后预测更准确(p<0.0001)。
要点
- GOLD 2017的3年全因死亡率从A组10.0%升至D组36.9%,但B组23.8%高于C组17.4%,ABCD分组并非单调递增。
- 以A组为参照,全因死亡调整HR:B组2.05(95%CI 1.87-2.26)、C组1.47(1.31-1.65)、D组3.01(2.75-3.30)。
- 仅用ABCD分组时,GOLD 2017预测全因死亡AUC 0.63(95%CI 0.53-0.73),并不优于GOLD 2007的0.61(0.60-0.61)和2011的0.61(0.60-0.62)。
- 将2017版细分为16个亚组(1A至4D)后,预测死亡率比旧版更准确(p<0.0001)。
- 呼吸死亡AUC:GOLD 2017 0.65(95%CI 0.53-0.78),GOLD 2007 0.64(0.62-0.65),GOLD 2011 0.63(0.62-0.64)。
适用人群与场景
- 丹麦全国COPD门诊患者,年龄≥30岁,主要诊断为COPD(ICD-10 J44.X)或急性呼吸衰竭(ICD-10 J96.X)合并COPD为次要诊断,且FEV1、体重指数、改良医学研究委员会呼吸困难量表评分和吸烟状态数据完整。
- 全因死亡主队列33765例,2008年1月1日至2013年11月30日;呼吸特异性死亡亚队列22621例,2008年1月1日至2011年12月31日。
诊断标准与关键阈值
- GOLD 2017分类将肺功能1-4级与基于症状和急性加重史的ABCD分组分开;ABCD分组依据改良医学研究委员会呼吸困难量表评分和急性加重史,肺功能分级依据FEV1。
- 研究进一步将GOLD 2017分为16个亚组(1A至4D)。
研究设计与关键结果
- 全国队列研究,纳入33765例COPD门诊患者(全因死亡主队列),其中22621例有呼吸特异性死亡数据(亚队列)。
- GOLD 2017的3年全因死亡率:A组10.0%、B组23.8%、C组17.4%、D组36.9%;呼吸死亡率:A组3.0%、B组9.7%、C组6.4%、D组18.0%。
- 以A组为参照,全因死亡调整HR:B组2.05(95%CI 1.87-2.26)、C组1.47(1.31-1.65)、D组3.01(2.75-3.30)。
- 全因死亡AUC:GOLD 2007 0.61(95%CI 0.60-0.61)、GOLD 2011 0.61(0.60-0.62)、GOLD 2017 0.63(0.53-0.73);呼吸死亡AUC:GOLD 2007 0.64(0.62-0.65)、GOLD 2011 0.63(0.62-0.64)、GOLD 2017 0.65(0.53-0.78)。
- 仅用ABCD分组时,GOLD 2017预测全因和呼吸死亡率并不优于GOLD 2007和2011;细分为16个亚组(1A至4D)后,新分类预测死亡率比旧版更准确(p<0.0001)。
证据类型、等级与局限
- 证据类型:全国队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:GOLD 2017的ABCD分类预测全因和呼吸死亡率并不比2007和2011版GOLD系统更准确。
- 作者报告:将GOLD 2017细分为16个亚组(1A至4D)后,预测死亡率比旧版更准确(p<0.0001)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 classification separates the spirometric 1-4 staging from the ABCD groups defined by symptoms and exacerbations. Little is known about how this new classification predicts mortality in patients with chronic obstructive pulmonary disease (COPD). We aimed to establish the predictive ability of the GOLD 2017 classification, compared with earlier classifications, for all-cause and respiratory mortality, both when using its main ABCD groups and when further subdividing according to spirometric 1-4 staging.
METHODS: In this nationwide cohort study, we enrolled patients with COPD with data available in the Danish registry for COPD. To be included in this registry, individuals must have been outpatients in hospital-based pulmonary clinics in Denmark. Eligible patients were aged 30 years or older; had received a primary diagnosis of COPD (International Classification of Diseases [ICD]-10 J44.X) or acute respiratory failure (ICD-10 J96.X) in combination with COPD (ICD-10 J44.X) as a secondary diagnosis; and had complete data on FEV1, body-mass index, modified Medical Research Council dyspnoea scale score, and smoking status. We categorised eligible patients with complete data according to the 2007, 2011, and 2017 GOLD classifications at the first contact with an outpatient clinic. For the GOLD 2017 classification, we further subdivided the patients by spirometry into 16 subgroups (1A to 4D). We calculated adjusted hazard ratios (HRs) for all-cause and respiratory mortality and compared the predictive ability of the three GOLD classifications (2007, 2011, and 2017) using receiver operating curves.
FINDINGS: We enrolled 33 765 patients with COPD, who were outpatients in Danish hospitals between Jan 1, 2008, and Nov 30, 2013, in the main cohort assessed for all-cause mortality. 22 621 of these patients had data available on cause-specific mortality (respiratory) and were included in a subcohort followed from Jan 1, 2008, to Dec 31, 2011. For the GOLD 2017 classification, 3 year mortality increased with increasing exacerbations and dyspnoea from group A (all-cause mortality 10·0%, respiratory mortality 3·0%) to group D (all-cause mortality 36·9%, respiratory mortality 18·0%). However, 3 year mortality was higher for group B patients (all-cause mortality 23·8%, respiratory mortality 9·7%) than for group C patients (all-cause mortality 17·4%, respiratory mortality 6·4%). Compared with group A, adjusted HRs for all-cause mortality ranged from 2·05 (95% CI 1·87-2·26) for group B, to 1·47 (1·31-1·65) for group C, and to 3·01 (2·75-3·30) for group D. Area under the curve for all-cause mortality was 0·61 (95% CI 0·60-0·61) for GOLD 2007, 0·61 (0·60-0·62) for GOLD 2011, and 0·63 (0·53-0·73) for GOLD 2017. Area under the curve for respiratory mortality was 0·64 (0·62-0·65) for GOLD 2007, 0·63 (0·62-0·64) for GOLD 2011, and 0·65 (0·53-0·78) for GOLD 2017. The GOLD 2017 classification based on ABCD groups only did not predict mortality better than the earlier 2007 and 2011 GOLD classifications. However, when 16 subgroups (1A to 4D) were defined, the new classification predicted mortality more accurately than the previous systems (p<0·0001).
INTERPRETATION: We showed that the new GOLD 2017 ABCD classification does not predict all-cause and respiratory mortality more accurately than the previous GOLD systems from 2007 and 2011.
FUNDING: Danish Lung Association, Program for Clinical Research Infrastructure.
参考来源
- Gedebjerg A, Szépligeti SK, Wackerhausen LH, et al. Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study. Lancet Respir Med. 2018. PMID: 29331311. doi:10.1016/S2213-2600(18)30002-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。